Receptor binding profile of cyclazosin, a new alpha 1B-adrenoceptor antagonist

Eur J Pharmacol. 1995 Dec 4;287(1):13-6. doi: 10.1016/0014-2999(95)00471-7.

Abstract

The binding profile of cyclazosin, a new prazosin-related alpha 1-adrenoceptor antagonist, at alpha 1-, alpha 2-adrenoceptors, dopamine D2 and 5-HT1A receptors was compared to that of 5-methylurapidil, spiperone, risperidone and other prazosin-related ligands. In addition, cyclazosin was investigated at native and cloned alpha 1-adrenoceptor subtypes. Cyclazosin showed high specificity for alpha 1-adrenoceptors and a 10-15-fold selectivity for alpha 1B (alpha 1b)-adrenoceptors with respect to the alpha 1A (alpha 1a) subtype (pKi values of 9.23-9.57 and 8.18-8.41, respectively). However, it failed to discriminate between cloned alpha 1b and alpha 1d-adrenoceptors (pKi values of 9.23 and 9.28, respectively).

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic alpha-Antagonists / metabolism
  • Adrenergic alpha-Antagonists / pharmacology*
  • Animals
  • Brain / metabolism*
  • Male
  • Prazosin / metabolism
  • Prazosin / pharmacology
  • Quinazolines / metabolism
  • Quinazolines / pharmacology*
  • Quinoxalines / metabolism
  • Quinoxalines / pharmacology*
  • Rats
  • Receptors, Adrenergic, alpha-1 / metabolism

Substances

  • Adrenergic alpha-Antagonists
  • Quinazolines
  • Quinoxalines
  • Receptors, Adrenergic, alpha-1
  • cyclazosin
  • Prazosin